Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Parallel phase 2 studies demonstrate high response rates in transplant-eligible multiple myeloma patients, indicating Isa-RVd may reduce need for autologous stem cell transplant.
Key Points
The ≥VGPR rate after two induction cycles reached 61.9% in the DFCI study and 89.8% in the CTI study, showing strong efficacy.
In the CTI study, the MRD-negative rate was 37.5% post-induction, highlighting successful minimal residual disease targeting.
Observational analysis across phase 2 studies assessed safety and tolerability of Isa-RVd induction therapy in multiple myeloma patients.
Induction phase demonstrated good tolerability, with no new or unexpected safety issues, suggesting further study is warranted.